Repare Therapeutics Inc. (RPTX) Earnings History
Net Loss7 years of earnings data (2018–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Repare Therapeutics Inc. (RPTX) Earnings Overview
As of June 30, 2026, Repare Therapeutics Inc. (RPTX) reported trailing twelve-month net income of -$72M, reflecting +10.3% year-over-year growth. The company earned $-1.68 per diluted share over the past four quarters, with a net profit margin of -158.4%.
Looking at the long-term picture, RPTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2018.
Repare Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RVMD (-$1.37B net income), PMVP (-$78M net income), ACLX (-$229M net income, -1027.3% margin), RPTX has comparable earnings metrics. Compare RPTX vs RVMD →
RPTX Earnings vs Peers
Earnings metrics vs comparable public companies
RPTX Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$85M | +9.7% | -$94M | $-2.00 | -158.4% | -174.9% |
| 2023 | -$94M | -222.9% | -$116M | $-2.23 | -183.4% | -227.3% |
| 2022 | -$29M | +72.8% | -$20M | $-0.69 | -22.0% | -15.0% |
| 2021 | -$107M | -100.1% | -$109M | $-2.83 | -1406.7% | -1429.7% |
| 2020 | -$53M | -96.3% | -$54M | $-1.45 | -39568.1% | -40223.7% |
| 2019 | -$27M | -90.5% | -$26M | $-0.74 | - | - |
| 2018 | -$14M | - | -$13M | $-0.90 | - | - |
Download Data
Export RPTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RPTX — Frequently Asked Questions
Quick answers to the most common questions about buying RPTX stock.
What is RPTX earnings per share (EPS)?
RPTX trailing twelve-month (TTM) diluted EPS is $-1.68, reflecting +10.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2024 is available in the table on this page.
What is Repare Therapeutics Inc.'s net income?
Repare Therapeutics Inc. (RPTX) trailing twelve-month net income is $-72M as of 2024. Earnings grew +10.3% year-over-year.
Is RPTX profitable?
RPTX is not currently profitable on a TTM basis, reporting a net loss of $-72M. Net margin is -158.4%. Investors should monitor for a return to profitability.
What is RPTX's earnings growth rate?
RPTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2024.
What are RPTX's profit margins?
Repare Therapeutics Inc. net profit margin is -158.4%, operating margin is -174.9%, and gross margin is +75.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -46.6%.
Is RPTX growing earnings?
RPTX is growing earnings steadily. YoY EPS growth of +10.3% is consistent with the 5-year CAGR of N/A. TTM net income is $-72M.
What was RPTX's best earnings year?
Repare Therapeutics Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2024 and includes all annual and quarterly figures.
What were RPTX's earnings last quarter?
RPTX's most recent reported quarter was Q3 2025. Net income was $3M with diluted EPS of $0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.